Filgotinib

COMPOSITION:

Each film-coated tablet contains Filgotinib maleate 127.28mg equivalent to Filgotinib………………. 100 mg.

INDICATION:

• Rheumatoid arthritis

LuciFilgo is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).

• Ulcerative colitis

LuciFilgo is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

DOSAGE AND USE:

• Rheumatoid arthritis

The recommended dose of filgotinib for adult patients is 200 mg once daily.In adults at increased risk of VTE, MACE and malignancy, the recommended dose is 100 mg once daily and may be escalated to 200 mg once daily in case of insufficient disease control. For long term treatment, the lowest effective dose should be used.

• Ulcerative colitis

The recommended dose for induction treatment is 200 mg once daily.For patients with ulcerative colitis who do not show an adequate therapeutic benefit during the initial 10 weeks of treatment,12 additional weeks of induction treatment with filgotinib 200 mg once daily may provide additional relief of symptoms.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos.

WARNING:

Keep medicine out of reach of Children. Do not administer LuciFilgo during Pregnancy and Lactation.